Prescribing Gabapentin off Label: Perspectives from Psychiatry, Pain and Neurology Specialists

Overview

Journal Can Pharm J (Ott)

Specialty Pharmacology

Date 2013 Mar 20

PMID 23509590

Citations 18

Authors

Christine Fukada

Jillian Clare Kohler

Heather Boon

Zubin Austin

Murray Krahn

Affiliations

Soon will be listed here.

Abstract

Objective: The objective of the study was to explore the experiences of physicians prescribing gabapentin off label.

Methods: We used a case study approach to explore the experiences of physicians prescribing gabapentin for off-label indications. Semi-structured interviews were conducted with 10 physicians (psychiatry, pain and neurology specialists) in the Greater Toronto Area. Data were collected to the point of saturation of key themes and analyzed using interpretive content analysis.

Key Findings: Key informants appeared to rely primarily on informal information from colleagues and meetings, putting into question the accuracy of their information about the potential off-label uses of gabapentin. Our findings suggest the need for more evidence-based information on off-label drug use.

Conclusion: There is a need for greater understanding of off-label prescribing practices as an important step toward improving rational prescribing and ultimately toward improving patient safety and health outcomes.

Citing Articles

Efficacy of gabapentin and pregabalin for treatment of post refractive surgery pain: a systematic review and meta-analysis.

Chen K, Chan H, Wei L, Chan C Int Ophthalmol. 2024; 44(1):409.

PMID: 39448432 DOI: 10.1007/s10792-024-03300-9.

The Association of Gabapentin Initiation with Cognitive and Behavioral Changes in Older Adults with Cognitive Impairment: A Retrospective Cohort Study.

Oh G, Moga D, Fardo D, Harp J, Abner E Drugs Aging. 2024; 41(7):623-632.

PMID: 38980643 PMC: 11528691. DOI: 10.1007/s40266-024-01130-z.

Prediction of adverse events risk in patients with comorbid post-traumatic stress disorder and alcohol use disorder using electronic medical records by deep learning models.

Miranda O, Fan P, Qi X, Wang H, Brannock M, Kosten T Drug Alcohol Depend. 2024; 255:111066.

PMID: 38217979 PMC: 10853953. DOI: 10.1016/j.drugalcdep.2023.111066.

Prediction of Adverse Events Risk in Patients with Comorbid Post- Traumatic Stress Disorder and Alcohol Use Disorder Using Electronic Medical Records by Deep Learning Models.

Miranda O, Fan P, Qi X, Wang H, Brannock M, Kosten T Res Sq. 2023; .

PMID: 37790550 PMC: 10543461. DOI: 10.21203/rs.3.rs-3299369/v1.

Hierarchical Concept Relations Improve Detection of Off-Label Drug Use in Electronic Health Records Data.

Schiffer K, Choi Y, Weng C AMIA Jt Summits Transl Sci Proc. 2023; 2023:458-466.

PMID: 37350872 PMC: 10283126.

References

MacLeod S . Improving physician prescribing practices: bridge over troubled waters. CMAJ. 1996; 154(5):675-7. PMC: 1487562. View

Prosser H, Almond S, Walley T . Influences on GPs' decision to prescribe new drugs-the importance of who says what. Fam Pract. 2003; 20(1):61-8. DOI: 10.1093/fampra/20.1.61. View

Nightingale S . Off-label use of prescription drugs. Am Fam Physician. 2003; 68(3):425-7. View

Mason A . New medicines in primary care: a review of influences on general practitioner prescribing. J Clin Pharm Ther. 2008; 33(1):1-10. DOI: 10.1111/j.1365-2710.2008.00875.x. View

Moulin D, Clark A, Gilron I, Ware M, Watson C, Sessle B . Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag. 2007; 12(1):13-21. PMC: 2670721. DOI: 10.1155/2007/730785. View

Boos J . Off label use--label off use?. Ann Oncol. 2002; 14(1):1-5. DOI: 10.1093/annonc/mdg035. View

Radley D, Finkelstein S, Stafford R . Off-label prescribing among office-based physicians. Arch Intern Med. 2006; 166(9):1021-6. DOI: 10.1001/archinte.166.9.1021. View

Serradell J, Galle B . Prescribing for unlabeled indications. HMO Pract. 1993; 7(1):44-7. View

Greer A . The state of the art versus the state of the science. The diffusion of new medical technologies into practice. Int J Technol Assess Health Care. 1987; 4(1):5-26. DOI: 10.1017/s0266462300003202. View

10.

Chin M, Friedmann P, Cassel C, Lang R . Differences in generalist and specialist physicians' knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure. J Gen Intern Med. 1997; 12(9):523-30. PMC: 1497156. DOI: 10.1046/j.1525-1497.1997.07105.x. View

11.

Haw C, Stubbs J . A survey of the off-label use of mood stabilizers in a large psychiatric hospital. J Psychopharmacol. 2005; 19(4):402-7. DOI: 10.1177/0269881105053307. View

12.

Stone K, Viera A, Parman C . Off-label applications for SSRIs. Am Fam Physician. 2003; 68(3):498-504. View

13.

Mack A . Examination of the evidence for off-label use of gabapentin. J Manag Care Pharm. 2003; 9(6):559-68. PMC: 10437292. DOI: 10.18553/jmcp.2003.9.6.559. View

14.

Lewis P, Tully M . Uncomfortable prescribing decisions in hospitals: the impact of teamwork. J R Soc Med. 2009; 102(11):481-8. PMC: 2770359. DOI: 10.1258/jrsm.2009.090150. View

15.

Kos M, Wertheimer A, Mrhar A . Satisfaction with pharmacotherapy for approved and off-label indications--a Delphi study. Ann Pharmacother. 2005; 39(4):649-54. DOI: 10.1345/aph.1E455. View

16.

Davis S . Gabapentin may be appropriate for off-label uses. J Manag Care Pharm. 2003; 9(6):569-70. PMC: 10437250. DOI: 10.18553/jmcp.2003.9.6.569. View

17.

Gazarian M, Kelly M, McPhee J, Graudins L, Ward R, Campbell T . Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust. 2006; 185(10):544-8. DOI: 10.5694/j.1326-5377.2006.tb00689.x. View